NEM vs RNAZ · P/E 14, rev $13.43B vs $5.1M cap
Newmont Goldcorp Corp (NEM) versus Transcode Therapeutics Inc (RNAZ) — a side-by-side from cached financials, not a winner call.
Newmont Goldcorp Corp (NEM) is a gold company listed on NYSE.
Transcode Therapeutics Inc (RNAZ) is a biotechnology company listed on NASDAQ.
Latest reported NEM revenue for 2026-06-30 was $13.43B. Net income was $5.46B. Revenue was up 83.7% from 2026-03-31 to 2026-06-30. NEM currently screens at market cap $112.81B and trailing P/E 13.7.
RNAZ does not have a complete income-statement cache yet.
NEM currently screens at market cap $112.81B and trailing P/E 13.7. RNAZ currently screens at market cap $5.1M.
Not investment advice. Open the NEM and RNAZ stock pages for the full models.
Not investment advice.